182 related articles for article (PubMed ID: 30292979)
1. Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours.
Barriuso J; Custodio A; Afonso R; Alonso V; Astudillo A; Capdevila J; García-Carbonero R; Grande E; Jimenez-Fonseca P; Marazuela M; Rodríguez-Antona C; Aller J
Cancer Treat Rev; 2018 Nov; 70():209-222. PubMed ID: 30292979
[TBL] [Abstract][Full Text] [Related]
2. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
3. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
Cives M; Soares HP; Strosberg J
Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin analogs for the treatment of neuroendocrine tumors.
Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
[TBL] [Abstract][Full Text] [Related]
5. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.
Gajate P; Alonso-Gordoa T; Martínez-Sáez O; Molina-Cerrillo J; Grande E
Clin Transl Oncol; 2018 May; 20(5):561-569. PubMed ID: 29124519
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
8. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
9. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms.
Modlin IM; Bodei L; Kidd M
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):59-77. PubMed ID: 26971844
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine tumors. Peptide receptor radionuclide therapy.
Forrer F; Valkema R; Kwekkeboom DJ; de Jong M; Krenning EP
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):111-29. PubMed ID: 17382268
[TBL] [Abstract][Full Text] [Related]
12. The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors.
Modlin IM; Kidd M; Malczewska A; Drozdov I; Bodei L; Matar S; Chung KM
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):485-504. PubMed ID: 30098712
[TBL] [Abstract][Full Text] [Related]
13. Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors.
Hofland LJ; Vandamme T; Albertelli M; Ferone D
Front Horm Res; 2015; 44():216-38. PubMed ID: 26303715
[TBL] [Abstract][Full Text] [Related]
14. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Cives M; Strosberg J
Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
[TBL] [Abstract][Full Text] [Related]
15. Radioguided surgery and systemic radionuclide therapy of neuroendocrine tumours.
Hodolic M; Fettich J; Marzola MC; Tonini E; Al-Nahhas A; Rubello D
In Vivo; 2010; 24(1):97-100. PubMed ID: 20133983
[TBL] [Abstract][Full Text] [Related]
16. Drug Development in Neuroendocrine Tumors: What Is on the Horizon?
Garcia-Alvarez A; Hernando Cubero J; Capdevila J
Curr Treat Options Oncol; 2021 Mar; 22(5):43. PubMed ID: 33786683
[TBL] [Abstract][Full Text] [Related]
17. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
Lo Russo G; Pusceddu S; Prinzi N; Imbimbo M; Proto C; Signorelli D; Vitali M; Ganzinelli M; Maccauro M; Buzzoni R; Seregni E; de Braud F; Garassino MC
Tumour Biol; 2016 Oct; 37(10):12991-13003. PubMed ID: 27460087
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Bal CS; Gupta SK; Zaknun JJ
Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981
[TBL] [Abstract][Full Text] [Related]
20. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.
Malczewska A; Kos-Kudła B; Kidd M; Drozdov I; Bodei L; Matar S; Oberg K; Modlin IM
Adv Med Sci; 2020 Mar; 65(1):18-29. PubMed ID: 31841822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
